The Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial pipeline drugs market research report outlays comprehensive information on the Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Gastrointestinal, Metabolic Disorders, and Genito Urinary System which include the indications Epilepsy, Parkinson’s Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity, Subacute Necrotizing Encephalomyelopathy (Leigh Disease), and Kidney Fibrosis. It also reviews key players involved in Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial targeted therapeutics development with respective active and dormant or discontinued products.
The Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial pipeline targets constitutes close to eight molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 1, 3, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial overview
Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial is an enzyme that in humans is encoded by a gene PPIF. This is also known as Cyclophilin F and involved in mitochondrial functions where it encodes a mitochondrial matrix peptidyl-prolyl cis-trans isomerase, which is an enzyme that catalyzes the isomerization of peptidyl-prolyl bonds in proteins. Mitochondria are cellular organelles known as the “powerhouses of the cell” because they are involved in energy production. Proteins like PPIF play a role in the regulation of mitochondrial processes. PPIF is a member of the cyclophilin family, and it is known to be associated with the mitochondrial permeability transition pore (mPTP), a structure involved in the regulation of mitochondrial membrane permeability. The opening of mPTP is linked to processes such as apoptosis (programmed cell death) and the response to cellular stress. Dysregulation of these processes has been implicated in various diseases, including neurodegenerative disorders and cardiovascular diseases.
For a complete picture of Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
